SE0300207D0 - New use and composition - Google Patents

New use and composition

Info

Publication number
SE0300207D0
SE0300207D0 SE0300207A SE0300207A SE0300207D0 SE 0300207 D0 SE0300207 D0 SE 0300207D0 SE 0300207 A SE0300207 A SE 0300207A SE 0300207 A SE0300207 A SE 0300207A SE 0300207 D0 SE0300207 D0 SE 0300207D0
Authority
SE
Sweden
Prior art keywords
composition
new use
digalactosyldiacylglycerol
wounds
bilayer
Prior art date
Application number
SE0300207A
Other languages
English (en)
Swedish (sv)
Inventor
Mona Staahle-Baeckdahl
Johan Heilborn
Conny Bogentoft
Anders Carlsson
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20290232&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0300207(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE0300207A priority Critical patent/SE0300207D0/xx
Publication of SE0300207D0 publication Critical patent/SE0300207D0/xx
Priority to JP2006502781A priority patent/JP4750690B2/ja
Priority to US10/543,659 priority patent/US7452864B2/en
Priority to DK04705973.8T priority patent/DK1589987T3/da
Priority to PCT/SE2004/000111 priority patent/WO2004067025A1/fr
Priority to CN2004800032098A priority patent/CN1744913B/zh
Priority to SI200432154T priority patent/SI1589987T1/sl
Priority to ES04705973.8T priority patent/ES2467090T3/es
Priority to PT47059738T priority patent/PT1589987E/pt
Priority to CN201010150582A priority patent/CN101838326A/zh
Priority to CA2513598A priority patent/CA2513598C/fr
Priority to CN201510400952.7A priority patent/CN105079784B/zh
Priority to EP04705973.8A priority patent/EP1589987B1/fr
Priority to ZA200505830A priority patent/ZA200505830B/en
Priority to US12/232,215 priority patent/US8012933B2/en
Priority to US13/193,131 priority patent/US8506994B2/en
Priority to US13/938,120 priority patent/US8936807B2/en
Priority to CY20141100342T priority patent/CY1115142T1/el
Priority to US14/567,267 priority patent/US9125875B2/en
Priority to HK16105830.5A priority patent/HK1217661A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
SE0300207A 2003-01-29 2003-01-29 New use and composition SE0300207D0 (sv)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE0300207A SE0300207D0 (sv) 2003-01-29 2003-01-29 New use and composition
CN201510400952.7A CN105079784B (zh) 2003-01-29 2004-01-28 Cathelicidin ll-37及其衍生物在伤口愈合中的用途
EP04705973.8A EP1589987B1 (fr) 2003-01-29 2004-01-28 Utilisation de peptides derivés de la cathelicidine ll-37 pour le traitement des plaies chroniques
ES04705973.8T ES2467090T3 (es) 2003-01-29 2004-01-28 Uso de péptidos derivados de la catelicidina LL-37 para usar en el tratamiento de heridas crónicas
CA2513598A CA2513598C (fr) 2003-01-29 2004-01-28 Utilisation de la cathelicidine ll-37 et de derives associes pour une cicatrisation de plaie
DK04705973.8T DK1589987T3 (da) 2003-01-29 2004-01-28 Anvendelse af cathelicidin ll-37 peptid-derivativer til behandling af kroniske sår
PCT/SE2004/000111 WO2004067025A1 (fr) 2003-01-29 2004-01-28 Utilisation de la cathelicidine ll-37 et de derives associes pour une cicatrisation de plaie
CN2004800032098A CN1744913B (zh) 2003-01-29 2004-01-28 Cathelicidin ll-37及其衍生物在伤口愈合中的用途
SI200432154T SI1589987T1 (sl) 2003-01-29 2004-01-28 Uporaba katelicidin ll-37 peptidnih derivatov za uporabo pri zdravljenju kroniäśnih ran
JP2006502781A JP4750690B2 (ja) 2003-01-29 2004-01-28 創傷治癒のための、カテリシジンｌｌ−３７、および、それらの誘導体の使用
PT47059738T PT1589987E (pt) 2003-01-29 2004-01-28 Uso do péptido ll-37 de catelicidina e seus derivados no tratmento de feridas crónicas
CN201010150582A CN101838326A (zh) 2003-01-29 2004-01-28 Cathelicidin ll-37及其衍生物在伤口愈合中的用途
US10/543,659 US7452864B2 (en) 2003-01-29 2004-01-28 Use of the cathelicidin LL-37 and derivatives thereof for wound healing
ZA200505830A ZA200505830B (en) 2003-01-29 2005-07-20 Use of the cathelicidin LL-37 and derivatives thereof for wound healing
US12/232,215 US8012933B2 (en) 2003-01-29 2008-09-12 Use of the cathelicidin LL-37 and derivatives therof for wound healing
US13/193,131 US8506994B2 (en) 2003-01-29 2011-07-28 Use of the cathelicidin LL-37 and derivatives thereof for wound healing
US13/938,120 US8936807B2 (en) 2003-01-29 2013-07-09 Use of the cathelicidin LL-37 and derivatives thereof for wound healing
CY20141100342T CY1115142T1 (el) 2003-01-29 2014-05-15 Χρηση πεπτιδιων παραγωγων της καθελισιδινης ll-37 για τη θεραπεια χρονιων πληγων
US14/567,267 US9125875B2 (en) 2003-01-29 2014-12-11 Use of the cathelicidin LL-37 and derivatives thereof for wound healing
HK16105830.5A HK1217661A1 (zh) 2003-01-29 2016-05-23 及其衍生物在傷口癒合中的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300207A SE0300207D0 (sv) 2003-01-29 2003-01-29 New use and composition

Publications (1)

Publication Number Publication Date
SE0300207D0 true SE0300207D0 (sv) 2003-01-29

Family

ID=20290232

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300207A SE0300207D0 (sv) 2003-01-29 2003-01-29 New use and composition

Country Status (14)

Country Link
US (5) US7452864B2 (fr)
EP (1) EP1589987B1 (fr)
JP (1) JP4750690B2 (fr)
CN (3) CN1744913B (fr)
CA (1) CA2513598C (fr)
CY (1) CY1115142T1 (fr)
DK (1) DK1589987T3 (fr)
ES (1) ES2467090T3 (fr)
HK (1) HK1217661A1 (fr)
PT (1) PT1589987E (fr)
SE (1) SE0300207D0 (fr)
SI (1) SI1589987T1 (fr)
WO (1) WO2004067025A1 (fr)
ZA (1) ZA200505830B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US7777000B2 (en) * 2003-03-06 2010-08-17 The Regents Of The University Of California Anti-viral activity of cathelicidin peptides
JP4734245B2 (ja) * 2003-08-01 2011-07-27 ストラタテック コーポレーション 外因性ポリペプチドを発現するヒト皮膚等価物
JP4668902B2 (ja) 2003-08-07 2011-04-13 ヒーラー リミテッド 創傷治癒を促進するための薬剤組成物及び方法
US7776823B2 (en) * 2003-10-21 2010-08-17 The Regents Of The University Of California Human cathelicidin antimicrobial peptides
SE0401942D0 (sv) * 2004-07-28 2004-07-28 Lipopeptide Ab New antimicrobial peptide complexes
EP1846444A2 (fr) * 2004-12-22 2007-10-24 Lipopeptide AB Nouveaux agents et leur utilisation
PL1888033T3 (pl) * 2005-06-09 2014-09-30 Meda Ab Sposób i kompozycja do leczenia chorób zapalnych
US9044438B2 (en) 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
NZ566083A (en) 2005-08-29 2012-11-30 Healor Ltd Methods and compositions for prevention and treatment of diabetic and aged skin
WO2007148078A1 (fr) * 2006-06-20 2007-12-27 Lipopeptide Ab Utilisation de la protéine antimicrobienne de cathélicidine (hcap18) en tant qu'agent anticancéreux
WO2008073174A2 (fr) * 2006-09-08 2008-06-19 The Regents Of The University Of California Thérapie antimicrobienne
US20090318534A1 (en) * 2006-09-27 2009-12-24 The Regents Of The University Of California Methods and compositions for the treatment of skin diseases and disorders
US20100166708A1 (en) * 2007-02-20 2010-07-01 The Regents Of The University Of California Antimicrobial and anti-inflammatory therapies and compositions
CA2691645A1 (fr) * 2007-06-25 2008-12-31 Lipopeptide Ab Nouveaux produits medicaux
CA2696833A1 (fr) * 2007-07-15 2009-01-22 Yitzchak Hillman Traitement de maladie par des peptides antimicrobien ou leurs inhibiteurs
US20100310542A1 (en) * 2007-07-30 2010-12-09 Healor Ltd. Pharmaceutical Compositions for treating wouds and related methods
WO2010139195A1 (fr) * 2009-06-04 2010-12-09 The Chinese University Of Hong Kong Bactéries anti-inflammatoires
WO2011046983A2 (fr) 2009-10-12 2011-04-21 Smith Holdings, Llc Procédés et compositions de modulation de l'expression génique en utilisant des médicaments à base d'oligonucléotides administrés in vivo ou in vitro
CA2779433A1 (fr) * 2009-11-03 2011-05-12 Lipidor Ab Composition pour favoriser la cicatrisation d'une plaie
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
WO2012150890A1 (fr) * 2011-05-02 2012-11-08 Lipidor Ab Composition antibactérienne
US9278994B2 (en) * 2012-03-20 2016-03-08 Helix Biomedix, Inc Short antimicrobial lipopeptides
US8969290B2 (en) 2012-06-26 2015-03-03 Worcester Polytechnic Institute Matrix scaffold with antimicrobial activity
EP2821077A1 (fr) * 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Nanoparticules lipidiques pour la cicatrisation des plaies
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
WO2015075406A1 (fr) 2013-11-19 2015-05-28 Lipopeptide Ab Nouveau traitement d'ulcères chroniques
CN103920137B (zh) * 2014-04-28 2016-03-30 中国药科大学 一种具有抗耐药性革兰阳性细菌作用的药物组合物
WO2015183683A2 (fr) * 2014-05-27 2015-12-03 Indiana University Research And Technology Corporation Antagoniste peptidique de ll -37
CN104984321A (zh) * 2015-07-24 2015-10-21 中国药科大学 人源抗菌肽ll-37在制备治疗或预防血栓性疾病药物中的应用
CN105859867A (zh) * 2016-05-30 2016-08-17 黄石市中心医院 一种人源抗菌肽ll-37突变体及其应用
CN106519042A (zh) * 2016-12-29 2017-03-22 陕西慧康生物科技有限责任公司 人源胶原蛋白与抗菌肽的融合蛋白及其制备方法与编码基因
US20190300575A1 (en) 2018-03-29 2019-10-03 Deetex, LLC Lytic peptide biosensor and methods of making and using the same
CN108659102B (zh) * 2018-04-25 2021-08-17 南方医科大学 具有抗菌及抗炎活性的多肽化合物
ES2799098B2 (es) 2019-06-10 2021-12-10 Univ Madrid Carlos Iii Aptameros agonistas del receptor fpr2 y usos de los mismos
KR102475936B1 (ko) * 2020-10-15 2022-12-09 코스맥스 주식회사 펩타이드 ll-37을 발현하는 효모를 포함하는 화장료 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
KR100220546B1 (ko) 1994-02-04 1999-09-15 벵 헤르슬로프 호지성 담체 제제
CZ285795B6 (cs) 1994-02-04 1999-11-17 Scotia Lipidteknik Ab Emulse oleje ve vodě, její použití a farmaceutický prostředek, který ji obsahuje
PT744939E (pt) 1994-02-04 2003-02-28 Lipocore Holding Ab Preparacoes em bicamada preparadas a partir de digalactosildiacilglicerol contendo galactolipido
SE9403055L (sv) 1994-09-13 1996-03-14 Hans G Boman Nytt humant peptidantibiotikum (fall-39) och dess användning
US5654273A (en) * 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair
CA2252467A1 (fr) * 1996-04-23 1997-10-30 Toray Industries, Inc. Agent anti-pylori
SE515982C2 (sv) * 1998-03-06 2001-11-05 Lipocore Holding Ab Användning av en olja-i-vatten emulsion som bärare för framställning av en topikal kräm eller lotion
US5925534A (en) * 1998-06-08 1999-07-20 Wako Pure Chemical Industries, Ltd. Method for measuring LDL-cholesterol
AU4013200A (en) * 1999-03-26 2000-10-16 Beth Israel Deaconess Medical Center Method for pr-39 peptide regulated stimulation of angiogenesis
AU2001287628A1 (en) 2000-07-17 2002-01-30 Hansa Medical Ab Antimicrobial agent
US8030537B1 (en) 2000-07-27 2011-10-04 Apogene Gmbh & Co. Kg Somatic cloning gene transfer for the production of recombinant proteins, cells and organs
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
US6835713B2 (en) * 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
US20030022829A1 (en) * 2001-03-30 2003-01-30 Wendy Maury Novel antiviral activities primate theta defensins and mammalian cathelicidins
WO2002095076A2 (fr) * 2001-05-23 2002-11-28 Kabushiki Kaisha Toyota Chuo Kenkyusho Polypeptides modifies presentant une resistance a la protease et/ou une sensibilite a la protease
EP1358888A1 (fr) * 2002-02-28 2003-11-05 Robert Bals L'Antibiotique peptidique humain LL-37/hCAP-18 est un inducteur de l'angiogénèse
GB0223655D0 (en) * 2002-10-10 2002-11-20 Mabtech Ab Method of diagnosis
JP2006514106A (ja) 2002-12-19 2006-04-27 ヒルマン，イチャク 抗菌ペプチド阻害剤による疾患治療
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition

Also Published As

Publication number Publication date
JP4750690B2 (ja) 2011-08-17
US20070149448A1 (en) 2007-06-28
SI1589987T1 (sl) 2014-07-31
ES2467090T3 (es) 2014-06-11
CN1744913B (zh) 2010-05-26
US20090088382A1 (en) 2009-04-02
US20110293707A1 (en) 2011-12-01
US8936807B2 (en) 2015-01-20
CN1744913A (zh) 2006-03-08
US8506994B2 (en) 2013-08-13
ZA200505830B (en) 2006-04-26
US20130287839A1 (en) 2013-10-31
DK1589987T3 (da) 2014-05-26
US7452864B2 (en) 2008-11-18
CN105079784B (zh) 2018-05-18
JP2006518375A (ja) 2006-08-10
CA2513598C (fr) 2015-04-21
WO2004067025A1 (fr) 2004-08-12
US8012933B2 (en) 2011-09-06
CA2513598A1 (fr) 2004-08-12
PT1589987E (pt) 2014-05-28
EP1589987A1 (fr) 2005-11-02
HK1217661A1 (zh) 2017-01-20
US9125875B2 (en) 2015-09-08
CY1115142T1 (el) 2016-12-14
CN101838326A (zh) 2010-09-22
EP1589987B1 (fr) 2014-04-23
US20150094256A1 (en) 2015-04-02
CN105079784A (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
SE0300207D0 (sv) New use and composition
EP3533461A3 (fr) Peptides dérivés de prame et compositions immunogènes les comportant
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
ATE427116T1 (de) Behandlung von bakteriellen infektionen
EP2567971A3 (fr) Vaccins de peptides avec Seq Id 80, 100 or 101 pour cancers exprimant des antigènes associés aux tumeurs
MX2009012675A (es) Tensioactivos reconstituidos que tienen propiedades mejoradas.
ES2688030T3 (es) Péptidos permeables celulares inhibidores de la ruta de transducción de la señal JNK para su uso en el tratamiento de enfermedades oculares inflamatorias
WO2006113681A3 (fr) Ligands de proteine de liaison a l'elastine derives de plantes et leurs procedes d'utilisation
EP3081214A3 (fr) Inhibiteurs de nécrose cellulaire
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
NZ593815A (en) Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
SG10201406288SA (en) Multimeric forms of antimicrobial peptides
AU2011267081A1 (en) Novel peptides for wound healing
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
ATE484290T1 (de) Peptid mit antitumoraler wirkung
AU2003251728A1 (en) Placental growth factor as a target for the treatment of osteoporosis
EP2212352B1 (fr) Nouveaux peptides synthétiques substitués par arginine et leur utilisation
RS52448B (en) ANTITUMOR PHARMACEUTICAL COMPOSITION CONTAINING SERALIZIN POLYPEPTIDE FRAGMENTS
EA200700413A1 (ru) Ариламинкетоны, способ их получения, фармацевтические композиции, содержащие их, и их применение
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
NZ585093A (en) Food material for inhibiting bone resorption
RU2008106460A (ru) Антимикробный агент, взаимодействующий с системой комплемента
WO2007101222A3 (fr) Traitement du cancer
WO2005092365A3 (fr) Utilisation pharmaceutique des novispirines
HK1123813A1 (en) Anti-tumor drug, medicament, composition, and use thereof